Chemotherapy Segment to Dominate Leukemia Therapeutics Market During Forecast Period
Increasing incidences of
cancer cases around the globe to drive the growth of global leukemia
therapeutics market
According
to TechSci Research report, “Global Leukemia
Therapeutics Market By Factor (Artificial ionizing radiation, Viruses,
Chemotherapy, Others), By Severity (Acute, Chronic), By Blood Cell
(Lymphocytic, Myelogenous), By Age Groups (0-15, 15-30, 30-50, 50+), By Sex
(Male, Female), By Treatment
(Targeted Therapy, Interferon Therapy, Radiation Therapy, Surgery, Stem Cell
Transplantation, Drugs, Gene Therapy, Others), By Diagnosis (Blood test,
Biopsy, Physical Exam, Imagining), By Route of Administration (Oral,
Intravenous, Subcutaneous, Intramuscular, Intrathecal), By Drugs
(Antimetabolites, Biosimilars, & Others), By Region, Forecast &
Opportunities, 2025”, the global leukemia
therapeutics market is expected to grow at a formidable rate during the
forecast period on account of the increasing prevalence of leukemia. Additionally,
drastic increase in the mortality rate due to leukemia is further expected to
propel the market during forecast period. Furthermore, strong developing
pipeline, increasing approvals of novel & innovative drugs and
immunotherapies are projected to spur the market during forecast years. Moreover,
technological advancements & innovations and faster approvals by the
regulatory agencies are further creating lucrative opportunities for the market.
However, lack of awareness among the population pertaining to the disease and
its severity can hamper the growth of market during forecast period.
Additionally, presence of generic drugs and limited availability of treatment
options restrict the growth of market over 2025. Furthermore, lack of early
diagnosis of the disease also obstruct the market growth over the next few
years. Moreover, the high cost of treatments and associated adverse effects are
further slowing down the growth of market.
Browse
XX market data Tables and XX Figures spread through XXX
Pages and an in-depth TOC on" Global
Leukemia Therapeutics Market"
https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html
The global leukemia therapeutics market is segmented based on factor,
severity, blood cell, age groups, sex, treatment, diagnosis, route of administration,
drugs, company and region. Based on blood cell, the market can be divided into lymphocytic
and myelogenous. The myelogenous segment is expected to dominate the market on
account of the large number of treatment options available for the treatment of
chronic myeloid leukemia and high incidence rate of chronic myeloid leukemia. Based
on age groups, the market can be segmented into 0-15, 15-30, 30-50 and 50+. The
30-50 years age group segment is expected to dominate the market since leukemia
mostly affects the middle age population. The 15-30 age group segment is
expected to witness growth on account of the drastic increase in the number of
patients of this age group suffering from leukemia. Based on sex, the market
can be bifurcated into male and female. The male segment dominates the market
since male population especially in their middle age are affected by this
disease. Leukemia is often regarded as the most common type of cancer in males.
Based on treatment, the market can be categorized into targeted therapy,
interferon therapy, radiation therapy, surgery, stem cell transplantation,
drugs, gene therapy, immunotherapy, vaccine therapy, chemotherapy and blood
transfusion. The chemotherapy segment is expected to dominate the market during
forecast period owing to an ability to kill cancerous cells or inhibiting its
proliferation and maintain a normal level of lymphocytes. Additionally, increased
survival rate of the patients treated with chemotherapy is again fueling the
demand for the segment. The targeted therapy segment is expected to register
the highest growth during the forecast period. This can be ascribed to the fewer
side effects and higher efficacy. Additionally, targeted therapy has a higher
success rate as compared to the other treatment options available.
Novartis, AbbVie, Bristol-Myers Squibb, Roche, Amgen, Gilead sciences,
Celgene, Eisai, AstraZeneca, Incyte Corporation, Johnson & Johnson, Biogen,
Merck, PerkinElmer, Eli Lilly, Abbott, Sumitomo Dainippon Pharma, Thermo Fisher
Scientific, Otsuka Holdings, Astellas Pharma and others are some of the leading
players operating in global leukemia therapeutics market. The companies operating
in the market are using organic strategies such as product launches, mergers
and collaborations to boost their share. For instance, In May 2018, Novartis
launched its CAR-T cell therapy for the second indication treatment of adult
patients with relapsed or refractory (r/r) large B-cell lymphoma. With the
innovative launch of Kymriah, Novartis is now a pioneer of leukemia
immunotherapies.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4534
Customers can also
request for 10% free customization on this report.
“Asia-Pacific is expected to witness
the highest growth in the leukemia therapeutics market during the forecast
period on account of the increasing investments in research and development for
the treatment of leukemia and the growing prevalence of leukemia in countries
such as Japan and India. Additionally, the increasing disposable income of
consumers and improving healthcare infrastructure in the region is further
expected to propel the market during forecast period. Also, growing focus of
market players on addressing healthcare based demands in these countries is
further expected to foster the growth of market through 2025.” said
Mr. Karan Chechi, Research Director with TechSci Research, a research based
global management consulting firm.
“Global Leukemia Therapeutics Market By Factor
(Artificial ionizing radiation, Viruses, Chemotherapy, Others), By Severity
(Acute, Chronic), By Blood Cell (Lymphocytic, Myelogenous), By Age Groups
(0-15, 15-30, 30-50, 50+), By Sex (Male, Female), By Treatment (Targeted Therapy, Interferon Therapy, Radiation
Therapy, Surgery, Stem Cell Transplantation, Drugs, Gene Therapy, Others), By
Diagnosis (Blood test, Biopsy, Physical Exam, Imagining), By Route of
Administration (Oral, Intravenous, Subcutaneous, Intramuscular, Intrathecal),
By Drugs (Antimetabolites, Biosimilars, & Others), By Region, Forecast
& Opportunities, 2025” has evaluated the future growth potential of global leukemia
therapeutics market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges and opportunities in global leukemia therapeutics
market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]